title: Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.
abstract: BACKGROUND
  To describe chemotherapy treatment patterns and clinical outcomes in metastatic soft tissue sarcoma (mSTS) patients with favorable response to chemotherapy.
  
  
  METHODS
  Multicenter (25) multi-country (9) retrospective chart review of mSTS patients with favorable response to chemotherapy, defined as stable disease or better following four cycles.
  
  
  RESULTS
  Two hundred and thirteen patients (58% female; mean age 54.7 years) received a mean of 2.7 lines of chemotherapy and 5.2 cycles per line. The most common first-line regimens were doxorubicin (34%) and anthracycline plus ifosfamide (30%). Favorable response was achieved by 83% to first-line and 42% and 38% in second- and third-line chemotherapy. The most common reason for chemotherapy discontinuation in lines with a favorable response was reaching a predefined number of cycles in first line (64% of 213) and disease progression in second or later lines (41% of 138). The mean time off chemotherapy was 38.0 weeks after first line, falling to 2.7-6.4 weeks in second or later lines. Median overall and progression-free survival were 23.5 (95% confidence interval 20.5-28.1) and 8.3 (7.4-9.9) months from first favorable response to chemotherapy.
  
  
  CONCLUSIONS
  mSTS patients achieving favorable response to chemotherapy have poor outcomes. Additional treatment options are needed.
authors.affiliation: Department of Medical Oncology, Christie Hospital, Manchester, UK. Electronic address: Michael.Leahy@christie.nhs.uktel.
authors.forename: M
authors.initials: M
authors.lastname: Leahy
authors.affiliation: Department of Medical Oncology, Instituto Catalan de Oncologia, Barcelona, Spain.
authors.forename: X
authors.initials: X
authors.lastname: Garcia Del Muro
authors.affiliation: Department of Hematology, Oncology and Palliative Care, Helios Klinikum, Bad Saarow, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Reichardt
authors.affiliation: Sarcoma Unit, Royal Marsden Hospital, London, UK.
authors.forename: I
authors.initials: I
authors.lastname: Judson
authors.affiliation: Pennsylvania Oncology Hematology Associates, Philadelphia, USA.
authors.forename: A
authors.initials: A
authors.lastname: Staddon
authors.affiliation: Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.affiliation: Epidemiology, Merck & Co., Inc., Upper Gwynedd, USA.
authors.forename: A
authors.initials: A
authors.lastname: Baffoe-Bonnie
authors.affiliation: OptumInsight, Stockholm, Sweden.
authors.forename: L
authors.initials: L
authors.lastname: Jönsson
authors.affiliation: OptumInsight, Stockholm, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Musayev
authors.affiliation: OptumInsight, Stockholm, Sweden.
authors.forename: N
authors.initials: N
authors.lastname: Justo
authors.affiliation: Global Health Outcomes, Merck & Co., Inc., Whitehouse Station, USA.
authors.forename: T
authors.initials: T
authors.lastname: Burke
authors.affiliation: Medical Oncology Department at the Centre Leon Berard, Université Claude Bernard, Lyon, France.
authors.forename: J Y
authors.initials: JY
authors.lastname: Blay
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009656:North America; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology